Immuno-Oncology CRO
Specialized support for complex immuno-oncology trial execution
Immuno-oncology (IO) is not a single therapeutic approach. Worldwide helps biopharma sponsors navigate the scientific, safety, and operational complexities of IO trials across multiple modalities, disease settings, and phases from first-in-human through late phase.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Immuno-Oncology Trial Challenges
Why Immuno-Oncology Trials Need More Specialized Support
IO trials require teams to navigate more than just complex cancer biology. IO agents act by modulating the immune system, which can make efficacy, toxicity, dosing strategies, and endpoint interpretation less straightforward than in many other oncology settings. Combination regimens introduce another layer of difficulty, especially when sponsors need to distinguish true treatment effects from overlapping safety signals. At the same time, factors such as biomarker-selected populations, stringent site requirements, advanced modality logistics, and long-term follow-up can all influence trial feasibility and execution. Worldwide supports sponsors in managing these challenges through IO-specific expertise, cross-functional planning, and operational support tailored to the real-world conduct of these trials.
IO Safety Needs Modality-Specific Planning
Immune-mediated toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and delayed reactions demand proactive planning, experienced oversight, and sites equipped for higher-acuity care. Worldwide helps sponsors anticipate and manage these risks from the outset.
Dose Strategy Is Not Always Straightforward
In IO development, dose decisions are not solely driven by maximum tolerated dose. Worldwide supports sponsors with study designs that enable dose optimization, expansion planning, and downstream development while preserving flexibility for future decisions.
Combination Development Increases Complexity
IO therapies are frequently developed in combination, whether with other IO agents, chemotherapy, targeted therapy, or radiation. Worldwide helps sponsors manage the added complexity around attribution, safety monitoring, and cross-functional execution that combination strategies can introduce.
Sites & Logistics Can Shape Feasibility
IO programs often rely on experienced investigators, higher-capability sites, biomarker-driven enrollment, and in some cases complex logistics or extended long-term follow-up. Worldwide helps sponsors plan for those operational realities early to support smoother trial execution.
Partnership & Approach
Integrated Support for Complex IO Programs
IO trials often require early alignment across scientific, safety, logistics, and operational considerations. Worldwide partners closely with sponsors to integrate these perspectives from the start, helping teams move with speed while protecting long-term development flexibility as the study progresses.
Studies in the Past 5 years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Fit for IO Complexity
Worldwide combines lung-specific operational expertise, global planning capabilities, and development experience to support sponsors in a highly competitive and clinically complex indication.
Built for Immuno-Oncology Complexity
IO spans a broad category including checkpoint inhibitors, cellular therapies, multispecific antibodies, T-cell engagers, tumor microenvironment approaches, cancer vaccines, gene therapies, oncolytic viruses, and combination regimens. Worldwide tailors its approach accordingly to match this diversity, aligning support with the specific demands of each modality.
of Active Oncology
Portfolio is IO
Safety Planning That Starts Early
IO trials often benefit from proactive, protocol-embedded planning around immune-mediated toxicities, site readiness, escalation decisions, and long-term follow-up. Worldwide helps sponsors build those considerations into study design and execution up front, rather than addressing challenges after they arise.
Real-Time Support for Decisions
IO development often depends on timely interpretation of emerging biological, safety, and operational data. Worldwide combines integrated planning with near-real-time data access, enabling sponsors to review findings, support decision-making, and adapt as the study evolves.
Support from First-in-Human Through Late Phase
Operationally Ready Across Modalities
Different IO modalities can bring different logistics, oversight, and site requirements. Worldwide helps sponsors navigate those advanced operational needs through a tailored approach that includes long-term follow-up and, where applicable, chain of custody requirements.
Continuity Across Programs
Worldwide supports IO development across both solid tumors and hematologic malignancies, maintaining continuity from early-stage planning through later-stage execution. This approach helps sponsors maintain scientific and operational alignment as programs evolve and expand.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Early Immuno-Oncology Study Execution
Worldwide helps sponsors plan and run IO studies with attention to dose strategy, expansion planning, protocol flexibility, startup considerations, and the key scientific questions that shape early development.
Immune Safety Oversight
Our teams provide modality-specific safety planning and oversight for immune-mediated toxicities, helping align protocol design, site readiness, and safety monitoring with study needs.
Site & Enrollment Strategy
Worldwide works with sponsors to identify IO-capable sites, experienced investigators, and enrollment strategies suited to biomarker-driven populations, higher-acuity care, and regional operational demands.
Logistics & Long-Term Follow-Up
For programs with advanced operational demands, Worldwide provides oversight of modality-specific logistics, vendor coordination, long-term follow-up, and chain of custody requirements where relevant.
What Our Clients Say
“I like that Worldwide is a mid sized CRO with all services under one umbrella and with a commitment to service their customers with priority — we’re not just a number.“
North American Emerging Biotech Company
FAQ & Insights
What Sponsors Need to Know
Worldwide helps sponsors design and execute early phase IO studies with attention to dose learning, escalation and expansion strategies, immune-mediated safety considerations, protocol flexibility, and the operational demands that can influence proof of concept and downstream development. The aim is to advance efficiently while preserving future strategic options.
Yes. Worldwide supports IO programs from first-in-human through late phase development across both solid tumors and hematologic malignancies. This continuity helps sponsors maintain alignment across scientific, safety, and operational planning as studies expand, combination approaches evolve, and programs advance.
IO trials require more than standard oncology execution, as mechanisms of action, toxicity profiles, dose strategies, and endpoint interpretation can differ significantly across modalities. Worldwide approaches IO as a diverse set of therapy classes and supports sponsors in addressing the specific scientific and operational implications of each mechanism.
Worldwide supports IO trials with planning and oversight built around immune-mediated risks, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), and delayed reactions. This includes protocol-aligned safety planning, attention to site readiness, and integrated operational support to help teams respond appropriately as safety data emerges.
IO trials often require experienced investigators, specialized site infrastructure, and the ability to manage complex safety and operational demands. Worldwide helps sponsors develop site and patient enrollment strategies that reflect these needs, including biomarker-driven recruitment, higher-acuity settings, and broader geographic reach.
Insights
Explore Our Immuno-Oncology Insights
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
